{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:18:06Z","timestamp":1791357486159,"version":"4.3.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006751","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental","doi-asserted-by":"publisher","award":["D1443L00079"],"award-info":[{"award-number":["D1443L00079"]}],"id":[{"id":"10.13039\/501100006751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.euroneuro.2017.08.429","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T01:45:11Z","timestamp":1504575911000},"page":"959-969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Results from a pilot, randomized controlled trial"],"prefix":"10.1016","volume":"27","author":[{"given":"Marina","family":"Garriga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Sol\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gonz\u00e1lez-Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Selva-Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Arranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt L.","family":"Amann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jer\u00f3nimo","family":"Saiz-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefina","family":"P\u00e9rez-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2017.08.429_bib1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1176\/appi.ajp.163.2.313","article-title":"Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants","volume":"163","author":"Altshuler","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders. Text Revision (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib3","first-page":"79","article-title":"The Spanish version of EuroQol: a description and its applications. European Quality of Life scale","volume":"112","author":"Badia","year":"1999","journal-title":"Med. Cl\u00edn."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib4","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry: J. Ment. Sci."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/HRP.0000000000000062","article-title":"Restoring functioning in bipolar disorder: functional remediation","volume":"22","author":"Bonnin","year":"2014","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib6","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1176\/appi.ajp.162.7.1351","article-title":"A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression","volume":"162","author":"Calabrese","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib7","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.clinthera.2011.10.002","article-title":"Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial","volume":"33","author":"Cutler","year":"2011","journal-title":"Clin. Ther."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1017\/S0033291798007429","article-title":"Subclinical symptoms in mood disorders: pathophysiological and therapeutic implications","volume":"29","author":"Fava","year":"1999","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.pnpbp.2008.09.026","article-title":"Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release","volume":"33","author":"Figueroa","year":"2009","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib10","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.4088\/JCP.13m08847","article-title":"Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo-controlled trial","volume":"75","author":"Gao","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib11","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s12264-014-1534-0","article-title":"Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat","volume":"31","author":"Gao","year":"2015","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib12","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/NMD.0b013e3181b3b3a0","article-title":"Validity and reliability of the Hamilton depression rating scale (5 items) for manic and mixed bipolar disorders","volume":"197","author":"Gonz\u00e1lez-Pinto","year":"2009","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib13","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(15)00241-X","article-title":"Bipolar disorder","volume":"387","author":"Grande","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/acps.12548","article-title":"Clinical features, impulsivity, temperament and functioning and their role in suicidality in patients with bipolar disorder","volume":"133","author":"Jim\u00e9nez","year":"2016","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib15","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/archpsyc.62.12.1322","article-title":"Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study","volume":"62","author":"Judd","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.57.6.553","article-title":"A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy","volume":"57","author":"Kapur","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jad.2010.10.026","article-title":"Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression","volume":"130","author":"Kemp","year":"2011","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib18","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jad.2015.11.002","article-title":"Treatment of bipolar disorder: review of evidence regarding quetiapine and lithium","volume":"191","author":"Ketter","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jad.2013.12.032","article-title":"Effect of quetiapine XR on depressive symptoms and sleep quality compared with lithium in patients with bipolar depression","volume":"157","author":"Kim","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib20","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s00213-016-4215-z","article-title":"Efficacy and safety of quetiapine extended release monotherapy in bipolar depression: a multi-center, randomized, double-blind, placebo-controlled trial","volume":"233","author":"Li","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib21","doi-asserted-by":"crossref","first-page":"A361","DOI":"10.1016\/S1098-3015(10)74775-6","article-title":"PMH56 a patient perspective on side effects of antipsychotic therapy: the tool instrument","volume":"12","author":"Lindstr\u00f6m","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.euroneuro.2015.01.007","article-title":"Cognition as a target in schizophrenia, bipolar disorder and depression","volume":"25","author":"Martinez-Aran","year":"2015","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4088\/JCP.08m04942gre","article-title":"A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II)","volume":"71","author":"McElroy","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib24","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S2215-0366(16)30264-4","article-title":"Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials","volume":"3","author":"McGirr","year":"2016","journal-title":"Lancet. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib25","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archpsyc.64.5.543","article-title":"Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication","volume":"64","author":"Merikangas","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hup.1091","article-title":"Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies","volume":"25","author":"Meulien","year":"2010","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib27","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry: J. Ment. Sci."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib28","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.psychres.2014.05.012","article-title":"Eye movement desensitization and reprocessing therapy in subsyndromal bipolar patients with a history of traumatic events: a randomized, controlled pilot-study","volume":"219","author":"Novo","year":"2014","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib29","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1176\/appi.ajp.2013.13020185","article-title":"The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders","volume":"170","author":"Pacchiarotti","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib30","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2165\/11208500-000000000-00000","article-title":"Quetiapine: a pharmacoeconomic review of its use in bipolar disorder","volume":"30","author":"Plosker","year":"2012","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib31","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib32","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1176\/ajp.2007.164.7.1035","article-title":"Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants","volume":"164","author":"Posner","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000449417","article-title":"Meta-analysis of the risk of subsequent mood episodes in bipolar disorder","volume":"86","author":"Radua","year":"2017","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib34","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.clinthera.2012.09.002","article-title":"Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study","volume":"34","author":"Riesenberg","year":"2012","journal-title":"Clin. Ther."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1745-0179-3-5","article-title":"Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder","volume":"3","author":"Rosa","year":"2007","journal-title":"Clin. Pract. Epidemiol. Ment. Health: CP EMH"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/acps.12568","article-title":"Course of residual symptoms according to the duration of euthymia in remitted bipolar patients","volume":"134","author":"Samalin","year":"2016","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib37","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jad.2016.12.054","article-title":"Residual depressive symptoms, sleep disturbance and perceived cognitive impairment as determinants of functioning in patients with bipolar disorder","volume":"210","author":"Samalin","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib38","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000228249","article-title":"Functioning and disability in bipolar disorder: an extensive review","volume":"78","author":"Sanchez-Moreno","year":"2009","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2017.01.010","article-title":"Do patients with bipolar disorder and subsyndromal symptoms benefit from functional remediation? A 12-month follow-up study","author":"Sanchez-Moreno","year":"2017","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib40","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/11207280-000000000-00000","article-title":"Quetiapine extended release: adjunctive treatment in major depressive disorder","volume":"25","author":"Sanford","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jad.2012.07.016","article-title":"Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient","volume":"145","author":"Sheehan","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib43","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0165-1781(97)00123-6","article-title":"Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP","volume":"73","author":"Spearing","year":"1997","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib44","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jad.2014.07.007","article-title":"Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression","volume":"168","author":"Suppes","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib45","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jad.2009.10.007","article-title":"Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression","volume":"121","author":"Suppes","year":"2010","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib46","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2147\/DDDT.S63779","article-title":"Quetiapine for acute bipolar depression: a systematic review and meta-analysis","volume":"8","author":"Suttajit","year":"2014","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib47","first-page":"11","article-title":"Quetiapine monotherapy for bipolar depression","volume":"4","author":"Thase","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib48","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/01.jcp.0000248603.76231.b7","article-title":"Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study)","volume":"26","author":"Thase","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib49","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1399-5618.2009.00726.x","article-title":"The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders","volume":"11","author":"Tohen","year":"2009","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib50","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.4088\/JCP.v69n1113","article-title":"Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study","volume":"69","author":"Tohen","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib51","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1399-5618.2007.00479.x","article-title":"Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study","volume":"9","author":"Vieta","year":"2007","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib52","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S2215-0366(16)30347-9","article-title":"Adjunctive antidepressants in bipolar depression","volume":"3","author":"Vieta","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.08.429_bib53","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/JCP.0b013e3181f15849","article-title":"Treatment options for bipolar depression: a systematic review of randomized, controlled trials","volume":"30","author":"Vieta","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib54","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/01.jcp.0000144887.66319.2f","article-title":"Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania","volume":"24","author":"Yatham","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib55","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2194-7511-1-10","article-title":"Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies","volume":"1","author":"Young","year":"2013","journal-title":"Int. J. Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2017.08.429_bib56","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry: J. Ment. Sci."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X17308969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X17308969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T19:37:03Z","timestamp":1668713823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X17308969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0924977X17308969"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.08.429","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Results from a pilot, randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.08.429","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}